作者
Curt D. Haffner,Adam K. Charnley,Christopher Aquino,Linda Casillas,M.A. Convery,Julie A. Cox,Mark A. Elban,Nicole C. Goodwin,Peter J. Gough,Pamela A. Haile,Terry V. Hughes,Beth Knapp‐Reed,Constantine Kreatsoulas,Ami S. Lakdawala,Huijie Li,Yiqian Lian,David B. Lipshutz,John F. Mehlmann,Michael T. Ouellette,Joseph J. Romano,Lisa M. Shewchuk,Arthur Y. L. Shu,Bartholomew J. Votta,Huiqiang Zhou,John Bertin,Robert W. Marquis
摘要
Herein we report the discovery of pyrazolocarboxamides as novel, potent, and kinase selective inhibitors of receptor interacting protein 2 kinase (RIP2). Fragment based screening and design principles led to the identification of the inhibitor series, and X-ray crystallography was used to inform key structural changes. Through key substitutions about the N1 and C5 N positions on the pyrazole ring significant kinase selectivity and potency were achieved. Bridged bicyclic pyrazolocarboxamide 11 represents a selective and potent inhibitor of RIP2 and will allow for a more detailed investigation of RIP2 inhibition as a therapeutic target for autoinflammatory disorders.